Roche awaits a high-risk, high-reward readout in autism, while for Ocular Therapeutix placebo ought to be easier to beat than active control.
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
The final month of 2018 will see FDA verdicts on Roche’s bid to play in the first-line lung cancer space, and what Jazz hopes will be its next big narcolepsy product.
Two oncology specialists, Epizyme and Clovis, have been punished for ongoing problems.
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.